Fairmont Banff Springs Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2018
Here are the related meetings in 2020:
Transforming Vaccinology (L2)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Emerging Technologies in Vaccine Discovery and Development (J5)
Organizer(s) David Kaslow, Nicholas Jackson and Ann L. Lee
January 28—February 1, 2018
Fairmont Banff Springs • Banff, AB Canada
Discounted Abstract Deadline: Oct 4, 2017
Abstract Deadline: Nov 2, 2017
Scholarship Deadline: Oct 4, 2017
Discounted Registration Deadline: Dec 6, 2017
Sponsored by Astellas Pharma Inc., Moderna Therapeutics and Pfizer Inc.
Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation
Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation
Joint Meeting:
Progress and Pathways Toward an Effective HIV Vaccine (J6)
Summary of Meeting:
Immunization remains one of the most effective preventive public health measures, the indirect effects of which are considered a global public good with an impressive net return over costs. Vaccines have contributed to “final public good”: eradication of two viruses and regional elimination of a half dozen or more other pathogens. The development of new vaccines, therefore, would seem an obvious priority area for use-inspired and applied biomedical research, yet the endeavor has become increasingly more challenging. The “easy vaccines have been made” belief, crowded vaccine schedules, escalating costs of full vaccination programs (particularly in cost-sensitive Gavi-eligible countries), and platforms for maternal immunization and Public Health Emergencies of International Concern have all contributed to an urgent need for new or improved approaches to the discovery, development and delivery of vaccines, particularly those that are cheaper, simpler to manufacture, and more convenient to use. The aim of this symposium is to provide a comprehensive survey of emerging tools from the most upstream antigen/vaccine discovery, to active and passive immunization platforms, clinical trials, and manufacturing, formulation and delivery, the desired outcome of which is to provide a forum for an integrated discussion on how best to meet the increasing challenges faced by the scientific community’s efforts in new vaccine development. The Keystone Symposia conference on “Emerging Technologies in Vaccine Discovery and Development” has been specifically paired with the conference on “HIV Vaccines” since discovering, developing and delivering an effective HIV vaccine may be one that benefits most from novel technologies, including new tools in structural immunology and interrogating human immune responses.
View Scholarships/Awards
Immunization remains one of the most effective preventive public health measures, the indirect effects of which are considered a global public good with an impressive net return over costs. Vaccines have contributed to “final public good”: eradication of two viruses and regional elimination of a half dozen or more other pathogens. The development of new vaccines, therefore, would seem an obvious priority area for use-inspired and applied biomedical research, yet the endeavor has become increasingly more challenging. The “easy vaccines have been made” belief, crowded vaccine schedules, escalating costs of full vaccination programs (particularly in cost-sensitive Gavi-eligible countries), and platforms for maternal immunization and Public Health Emergencies of International Concern have all contributed to an urgent need for new or improved approaches to the discovery, development and delivery of vaccines, particularly those that are cheaper, simpler to manufacture, and more convenient to use. The aim of this symposium is to provide a comprehensive survey of emerging tools from the most upstream antigen/vaccine discovery, to active and passive immunization platforms, clinical trials, and manufacturing, formulation and delivery, the desired outcome of which is to provide a forum for an integrated discussion on how best to meet the increasing challenges faced by the scientific community’s efforts in new vaccine development. The Keystone Symposia conference on “Emerging Technologies in Vaccine Discovery and Development” has been specifically paired with the conference on “HIV Vaccines” since discovering, developing and delivering an effective HIV vaccine may be one that benefits most from novel technologies, including new tools in structural immunology and interrogating human immune responses.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Sunday, January 28 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, February 1 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, February 2 in order to fully experience the meeting.
SUNDAY, JANUARY 28
MONDAY, JANUARY 29
TUESDAY, JANUARY 30
WEDNESDAY, JANUARY 31
THURSDAY, FEBRUARY 1
FRIDAY, FEBRUARY 2
Conference Program Print | View meeting in 24 hr (international) time
The meeting will begin on Sunday, January 28 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, February 1 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, February 2 in order to fully experience the meeting.
SUNDAY, JANUARY 28
6:00—8:00 PM
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
8:00—9:00 AM
Welcome and Keynote Address
*
David C. Kaslow,
PATH, USA
Penny M. Heaton,
Bill & Melinda Gates Medical Research Institute, USA
Introducing the Gates Medical Research Institute: A Vision for Accelerating Translational Development
Introducing the Gates Medical Research Institute: A Vision for Accelerating Translational Development
8:00—9:00 AM
Welcome and Keynote Address
*
M. Juliana McElrath,
Fred Hutchinson Cancer Research Center, USA
Michel C. Nussenzweig,
HHMI/Rockefeller University, USA
The HIV Vaccine Problem
The HIV Vaccine Problem
9:00—11:30 AM
New Tools in Antigen/Vaccine Discovery
*
Pamela J. Bjorkman,
California Institute of Technology, USA
Tobias R. Kollmann,
Telethon Kids Institute, Australia
Decoding the Human Immune System to Accelerate Vaccine Development
Decoding the Human Immune System to Accelerate Vaccine Development
Coffee Break
Simon Delagrave,
Sanofi Pasteur, USA
Novel Antigen Design and Functional Immune Assessments
Novel Antigen Design and Functional Immune Assessments
Rafick-Pierre Sekaly,
Case Western Reserve University, USA
Systems Biology and Vaccine Discovery
Systems Biology and Vaccine Discovery
Sarah F. Andrews,
National Institutes of Health, USA
Short Talk: Single-Cell Characterization of the Recall and de novo Responses in Humans to Influenza Hemagglutinin
Short Talk: Single-Cell Characterization of the Recall and de novo Responses in Humans to Influenza Hemagglutinin
Hana Golding,
US Food and Drug Administration, USA
Short Talk: Impact of AS03 Adjuvant on Antibody Repertoires and Affinity Maturation Against H5N1 Pandemic Influenza Vaccines and Heterologous Neutralization
Short Talk: Impact of AS03 Adjuvant on Antibody Repertoires and Affinity Maturation Against H5N1 Pandemic Influenza Vaccines and Heterologous Neutralization
9:00—11:30 AM
Laying the Foundation for an HIV Vaccine
Coffee Break
Barton F. Haynes,
Duke University Medical Center, USA
Host Controls of Broadly Neutralizing Antibodies
Host Controls of Broadly Neutralizing Antibodies
*
M. Juliana McElrath,
Fred Hutchinson Cancer Research Center, USA
Early Clinical Concepts to Advanced Stage HIV Vaccine Studies
Early Clinical Concepts to Advanced Stage HIV Vaccine Studies
Daniel Stieh,
Johnson & Johnson, Netherlands
Short Talk: Interim Immunogenicity Analysis of TRAVERSE: A Randomized, Parallel-Group, Placebo-Controlled, Double-Blind phase 1/2a Study in HIV Uninfected Adults to Assess Safety/Tolerability and Immunogenicity of Two Different Prime/Boost Regimens
Short Talk: Interim Immunogenicity Analysis of TRAVERSE: A Randomized, Parallel-Group, Placebo-Controlled, Double-Blind phase 1/2a Study in HIV Uninfected Adults to Assess Safety/Tolerability and Immunogenicity of Two Different Prime/Boost Regimens
Tomas Hanke,
University of Oxford, UK
Short Talk: Clinical Development of the First -Generation Conserved Region T Cell Vaccines
Short Talk: Clinical Development of the First -Generation Conserved Region T Cell Vaccines
2:30—4:30 PM
Workshop 1: Assessing Immunogenicity in Animals to Predict Outcomes in Humans
*
Richard Malley,
Boston Children's Hospital, USA
Lenny Moise,
EpiVax, USA
Immune Engineered H7N9 Influenza Hemagglutinin Overcomes Poor Vaccine Immunogenicity
Immune Engineered H7N9 Influenza Hemagglutinin Overcomes Poor Vaccine Immunogenicity
Clare N. Burn,
Albert Einstein College of Medicine, USA
An HSV Vaccine Candidate Deleted in Glycoprotein D Elicits High Titer FcγRIV-Activating Antibodies that Protect against HSV Challenge: A Role for HVEM in Functional Immune Responses
An HSV Vaccine Candidate Deleted in Glycoprotein D Elicits High Titer FcγRIV-Activating Antibodies that Protect against HSV Challenge: A Role for HVEM in Functional Immune Responses
Ian Francis,
Boston University, USA
Neisseria Gonorrhoeae Outer Membrane Vesicles Lacking RMP Show Promise as a Vaccine Antigen
Neisseria Gonorrhoeae Outer Membrane Vesicles Lacking RMP Show Promise as a Vaccine Antigen
Raphael Simon,
University of Maryland School of Medicine, USA
Preclinical Development of a Glycoconjugate Vaccine for Sub-Saharan Africa to Prevent Typhoid and Invasive Nontyphoidal Salmonella Disease
Preclinical Development of a Glycoconjugate Vaccine for Sub-Saharan Africa to Prevent Typhoid and Invasive Nontyphoidal Salmonella Disease
Emmanuel Amlabu,
University of Ghana, Ghana
Functional Characterization of Plasmodium Falciparum Surface Related Protein (PfSRP) as a Potential Blood-Stage Vaccine Target
Functional Characterization of Plasmodium Falciparum Surface Related Protein (PfSRP) as a Potential Blood-Stage Vaccine Target
Mariette Barbier,
West Virginia University, USA
Development of Vaccines against P. Aeruginosa based on Iron Acquisition
Development of Vaccines against P. Aeruginosa based on Iron Acquisition
Jian-Dong Huang,
University of Hong Kong, China
Combination of Multiple Antigens are Essential for the Development of a Novel Vaccine Against Staphylococcus aureus Infection
Combination of Multiple Antigens are Essential for the Development of a Novel Vaccine Against Staphylococcus aureus Infection
5:00—7:00 PM
Structural Immunology Guiding Vaccine Development (Joint)
*
Pamela J. Bjorkman,
California Institute of Technology, USA
Structural Studies of Antibody and Receptor Binding to HIV-1 Env
Structural Studies of Antibody and Receptor Binding to HIV-1 Env
Jason S. McLellan,
University of Texas at Austin, USA
Structure-Based Vaccine Design for Class I Viral Fusion Glycoproteins
Structure-Based Vaccine Design for Class I Viral Fusion Glycoproteins
Andrew B. Ward,
The Scripps Research Institute, USA
Using Structures to Guide Env Immunogen Design and Redesign
Using Structures to Guide Env Immunogen Design and Redesign
Walther Mothes,
Yale University School of Medicine, USA
Short Talk: Associating HIV-1 Env Trimer Structures with Functional Env Conformational States by smFRET Analysis
Short Talk: Associating HIV-1 Env Trimer Structures with Functional Env Conformational States by smFRET Analysis
7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
8:00—11:30 AM
New Platforms for Active Immunization
*
Louis J. Picker,
Oregon Health & Science University, USA
Klaus Früh,
Oregon Health & Science University, USA
CMV-Vectored Vaccines for Eliciting Cellular Immunity
CMV-Vectored Vaccines for Eliciting Cellular Immunity
Justin Moran,
Pfizer Inc., USA
Multi-Component Vaccines Are the Future but Pose Development Challenges
Multi-Component Vaccines Are the Future but Pose Development Challenges
Coffee Break
Richard Malley,
Boston Children's Hospital, USA
Generating Broad B- and T-Cell Immunity via the Multiple Antigen-Presenting System (MAPS)
Generating Broad B- and T-Cell Immunity via the Multiple Antigen-Presenting System (MAPS)
Christine Shaw,
Moderna, USA
Targeting Viral Pathogens with mRNA-Based Vaccines
Targeting Viral Pathogens with mRNA-Based Vaccines
Tong-Ming Fu,
Merck Research Laboratories, USA
Short Talk: A Replication-Defective Human Cytomegalovirus Vaccine for Prevention of Congenital Infection
Short Talk: A Replication-Defective Human Cytomegalovirus Vaccine for Prevention of Congenital Infection
Nadia Oreshkova,
Leiden University Medical Center, Netherlands
Short Talk: Engineering Yellow Fever Virus 17D-based RNA Replicons into an Innovative DNA-Launched Vaccine Vector Platform
Short Talk: Engineering Yellow Fever Virus 17D-based RNA Replicons into an Innovative DNA-Launched Vaccine Vector Platform
Jean-Philippe Julien,
Hospital for Sick Children Research Institute, Canada
Short Talk: Structural Studies of Human Antibody Responses to Malaria Vaccine Antigen PfCSP
Short Talk: Structural Studies of Human Antibody Responses to Malaria Vaccine Antigen PfCSP
8:00—11:00 AM
Germinal Centers, B/T Cell Interactions
*
Shane Crotty,
La Jolla Institute for Immunology, USA
Assessing the Engines of Affinity Maturation: Germinal Centers and Tfh Cells
Assessing the Engines of Affinity Maturation: Germinal Centers and Tfh Cells
Gabriel D. Victora,
Rockefeller University, USA
Clonal and Cellular Dynamics of Germinal Center Selection
Clonal and Cellular Dynamics of Germinal Center Selection
Coffee Break
Facundo D. Batista,
Ragon Institute of MGH, MIT and Harvard, USA
B Cell Activation Induces a Switch from Canonical to Non-Canonical Autophagy that Shapes B Cell Fate
B Cell Activation Induces a Switch from Canonical to Non-Canonical Autophagy that Shapes B Cell Fate
Kimberly M. Cirelli,
La Jolla Institute for Immunology, USA
Short Talk: Sustained Delivery Immunization Enhances Germinal Center and Antibody Responses to Env in rhesus macaques
Short Talk: Sustained Delivery Immunization Enhances Germinal Center and Antibody Responses to Env in rhesus macaques
Omolara Olujimi Baiyegunhi,
University of KwaZulu-Natal, South Africa
Short Talk: Early Initiation of Antiretroviral Therapy during Hyperacute HIV-1 Infection Preserves T Follicular Helper Cell Function
Short Talk: Early Initiation of Antiretroviral Therapy during Hyperacute HIV-1 Infection Preserves T Follicular Helper Cell Function
Ben Read,
Massachusetts Institute of Technology, USA
Short Talk: Nanoparticle Delivery, Glycosylation and Host Complement Target Env Immunogens to the Germinal Center
Short Talk: Nanoparticle Delivery, Glycosylation and Host Complement Target Env Immunogens to the Germinal Center
11:15 AM—1:00 PM
Hands-On Computer Session on Los Alamos Sequence Database
HIV Database Workshop presented by Los Alamos National Laboratory staff. Topics include:
• HIV Sequence Database
• Bioinformatics tools that have general application
Users can register for either or both workshops. Bring your own laptop.
2:30—4:30 PM
Workshop 2: Epidemic Preparedness Innovation
*
David C. Kaslow,
PATH, USA
Just-in-Time and Just-in-Case Vaccines Approaches to Epidemic Preparedness
Just-in-Time and Just-in-Case Vaccines Approaches to Epidemic Preparedness
Christine Dahlke,
University Medical Center Hamburg-Eppendorf, Germany
Human miRNome Profiling Identifies a MicroRNA Signature Induced by the Ebola Vaccine rVSV-EBOV
Human miRNome Profiling Identifies a MicroRNA Signature Induced by the Ebola Vaccine rVSV-EBOV
Tulika Singh,
Duke University, USA
Transplacental Transfer of IgG in the Setting of Zika Virus Infection during Pregnancy
Transplacental Transfer of IgG in the Setting of Zika Virus Infection during Pregnancy
Neal Scott Van Hoeven,
Infectious Disease Research Institute, USA
Development of a Flexible Replicating Viral RNA Vaccine Platform and Generation of a Candidate Vaccine for Zika Virus
Development of a Flexible Replicating Viral RNA Vaccine Platform and Generation of a Candidate Vaccine for Zika Virus
Emma M. Kennedy,
Public Health England, UK
Development of a Vaccine for Lassa Fever using Modified Vaccinia Ankara Virus as a Vector
Development of a Vaccine for Lassa Fever using Modified Vaccinia Ankara Virus as a Vector
Nianshuang Wang,
University of Texas at Austin, USA
Structure-Based Design of Prefusion Coronavirus Spikes with Enhanced Expression, Stability and Immunogenicity
Structure-Based Design of Prefusion Coronavirus Spikes with Enhanced Expression, Stability and Immunogenicity
Jingjing Jiang,
Inovio Pharmaceuticals, USA
Immunogenicity of a Multivalent Mosquito-Borne Virus DNA Vaccine in Non-Human Primates
Immunogenicity of a Multivalent Mosquito-Borne Virus DNA Vaccine in Non-Human Primates
2:30—4:30 PM
Workshop 1: Laying the Groundwork for Vaccine Design
*
Marie Pancera,
Fred Hutchinson Cancer Research Center, USA
*
Michael Farzan,
The Scripps Research Institute, USA
Christopher A. Cottrell,
The Scripps Research Institute, USA
Using High-Resolution Cryo-Electron Microscopy to Guide Iterative Structure-Based HIV Vaccine Design
Using High-Resolution Cryo-Electron Microscopy to Guide Iterative Structure-Based HIV Vaccine Design
Christopher O. Barnes,
California Institute of Technology, USA
Structural Characterization of a Highly Potent V3-Targeting Broadly Neutralizing Antibody Bound to Natively-Glycosylated HIV-1 Envelope
Structural Characterization of a Highly Potent V3-Targeting Broadly Neutralizing Antibody Bound to Natively-Glycosylated HIV-1 Envelope
Jose Maximiliano Medina-Ramírez,
University of Amsterdam, Netherlands
Sequential Vaccination Regimens Based on Multiclade Germline-Targeting Trimers and Affinity Intermediates to Guide bNAb Development
Sequential Vaccination Regimens Based on Multiclade Germline-Targeting Trimers and Affinity Intermediates to Guide bNAb Development
Jason J. Gorman,
NIAID, National Institutes of Health, USA
Stabilization of Soluble SIV Envelope Trimers
Stabilization of Soluble SIV Envelope Trimers
Wilton B. Williams,
Duke University, USA
SHIV-CH848 Infection of Rhesus Macaques Recapitulates HIV-1 Env-Antibody Co-Evolution of Humans
SHIV-CH848 Infection of Rhesus Macaques Recapitulates HIV-1 Env-Antibody Co-Evolution of Humans
Tara A. Bancroft,
Fred Hutchinson Cancer Research Center, USA
Detection and in vivo Activation of Naive B Cells Expressing Putative Germline Precursors of a Neutralizing Antibody using Anti-Idiotypes
Detection and in vivo Activation of Naive B Cells Expressing Putative Germline Precursors of a Neutralizing Antibody using Anti-Idiotypes
Devin Sok,
International AIDS Vaccine Initiative, USA
Non-human Primate Pharmacokinetics Evaluation of Broadly Neutralizing Antibodies Isolated from Cow Immunizations
Non-human Primate Pharmacokinetics Evaluation of Broadly Neutralizing Antibodies Isolated from Cow Immunizations
Claudia Cicala,
NIAID, National Institutes of Health, USA
Select gp120 V2 Domain Specific Antibodies Derived from HIV and SIV Infection and Vaccination Inhibit gp120 Binding to Integrin α4β7
Select gp120 V2 Domain Specific Antibodies Derived from HIV and SIV Infection and Vaccination Inhibit gp120 Binding to Integrin α4β7
5:00—7:00 PM
New Platforms for Passive Immunization
*
Charles Richter King,
PATH, Malaria Vaccine Initiative, USA
JoAnn A. Suzich,
AstraZeneca, USA
Multi-Mechanistic Monoclonal Antibody-Based Approaches for Passive Immunoprophylaxis
Multi-Mechanistic Monoclonal Antibody-Based Approaches for Passive Immunoprophylaxis
Alejandro Balazs,
Massachusetts General Hospital, USA
Development of Vectored Immunotherapy Reveals Escapability as a Key Feature of Broadly Neutralizing Antibodies
Development of Vectored Immunotherapy Reveals Escapability as a Key Feature of Broadly Neutralizing Antibodies
Amar Kumar Garg,
Indian Institute of Science, India
Short Talk: Stochastic Simulation of Affinity Maturation in Germinal Centers Suggest Optimal Passive Immunization Protocols
Short Talk: Stochastic Simulation of Affinity Maturation in Germinal Centers Suggest Optimal Passive Immunization Protocols
Steven E. Bosinger,
Emory University, USA
Short Talk: BALDR - A Computational Pipeline for Linking Paired Immunoglobulin Heavy and Light Chain to Gene Expression for Single-Cells in Vaccine Studies
Short Talk: BALDR - A Computational Pipeline for Linking Paired Immunoglobulin Heavy and Light Chain to Gene Expression for Single-Cells in Vaccine Studies
Cody S. Nelson,
Duke University, USA
Short Talk: HCMV Glycoprotein B Vaccine Efficacy Likely Mediated by Non-Neutralizing Antibody Effector Functions
Short Talk: HCMV Glycoprotein B Vaccine Efficacy Likely Mediated by Non-Neutralizing Antibody Effector Functions
5:00—7:00 PM
Model Systems for HIV Vaccine Development
*
George M. Shaw,
University of Pennsylvania, USA
Recapitulation of HIV-1 Envelope-Antibody Coevolution in Rhesus Macaques Leading to Strain-Specific and Broadly Neutralizing Antibodies
Recapitulation of HIV-1 Envelope-Antibody Coevolution in Rhesus Macaques Leading to Strain-Specific and Broadly Neutralizing Antibodies
Pia Dosenovic,
Rockefeller University, USA
Activation of HIV-1-Specific B Cell Precursors in the Presence of a Polyclonal Immune System
Activation of HIV-1-Specific B Cell Precursors in the Presence of a Polyclonal Immune System
Ann J. Hessell,
Oregon Health & Science University, USA
Short Talk: Targeting V1V2 Epitopes for the Development of an Effective HIV Vaccine
Short Talk: Targeting V1V2 Epitopes for the Development of an Effective HIV Vaccine
7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
8:00—11:00 AM
New Tools in Interrogating Human Immune Responses (Joint)
*
Bette Tina Marie Korber,
Los Alamos National Laboratory, USA
Computational Tools for Antigen Design
Computational Tools for Antigen Design
Mohammad M. Sajadi,
University of Maryland School of Medicine, USA
The Circulating Antibody Repertoire: Tools of the Trade
The Circulating Antibody Repertoire: Tools of the Trade
Coffee Break
Louis J. Picker,
Oregon Health & Science University, USA
Immune Programming with CMV Vectors
Immune Programming with CMV Vectors
Anna P. Durbin,
Johns Hopkins Bloomberg School of Public Health, USA
Characterizing the Cellular and Humoral Response of Human Volunteers following Dengue Vaccination and Challenge in a Dengue Controlled Human Infection Model
Characterizing the Cellular and Humoral Response of Human Volunteers following Dengue Vaccination and Challenge in a Dengue Controlled Human Infection Model
Ian Setliff,
Vanderbilt Vaccine Center, USA
Short Talk: Identification of Public Antibody Clonotypes in HIV-1 Infection
Short Talk: Identification of Public Antibody Clonotypes in HIV-1 Infection
11:30 AM—1:00 PM
Hands-On Computer Session on Los Alamos Immunology Database
HIV Database Workshop presented by Los Alamos National Laboratory staff Topics include:
• HIV Immunology Database
• Immunology and vaccine design tools that have general application
Users can register for either or both workshops. Bring your own laptop.
2:30—4:30 PM
Workshop 2: Clinical and Preclinical Vaccine Studies
*
Nancy L. Haigwood,
Oregon Health & Science University, USA
*
Alejandro Balazs,
Massachusetts General Hospital, USA
Andrew Jones,
Emory University, USA
Sublingual and Buccal Delivery of MVA/Protein HIV Vaccination with a Needle-Free Injector Induces Robust Systemic and Mucosal Antibody Responses in Rhesus Macaques
Sublingual and Buccal Delivery of MVA/Protein HIV Vaccination with a Needle-Free Injector Induces Robust Systemic and Mucosal Antibody Responses in Rhesus Macaques
Barbara K. Felber,
NCI, National Institutes of Health, USA
DNA+Protein HIV Vaccine Protection against SHIV Challenge upon Same-Site Administration in Macaques
DNA+Protein HIV Vaccine Protection against SHIV Challenge upon Same-Site Administration in Macaques
Matthias Georg Pauthner,
The Scripps Research Institute, USA
Vaccine-Induced Protection from Autologous Tier 2 SHIV-BG505 Challenge
Vaccine-Induced Protection from Autologous Tier 2 SHIV-BG505 Challenge
Keyun Wang,
NIAID, National Institutes of Health, USA
Trispecific Broadly Neutralizing HIV Antibodies Mediate Potent SHIV Protection in Macaques
Trispecific Broadly Neutralizing HIV Antibodies Mediate Potent SHIV Protection in Macaques
Kristen W. Cohen,
Fred Hutchinson Cancer Research Center, USA
Expansion of VH1-2*02 Env-Specific B Cells by Vaccination
Expansion of VH1-2*02 Env-Specific B Cells by Vaccination
Tongqing Zhou,
NIAID, National Institutes of Health, USA
Priming with Glycan-deleted HIV-1 Env Trimers and Sequential Boosting with Glycan-Restored Immunogens Induces Immune Responses that Neutralize Diverse Tier-2 Viruses
Priming with Glycan-deleted HIV-1 Env Trimers and Sequential Boosting with Glycan-Restored Immunogens Induces Immune Responses that Neutralize Diverse Tier-2 Viruses
Daniel P. Leaman,
The Scripps Research Institute, USA
Membrane Env Liposomes as a Platform for Immunization with Membrane-Incorporated HIV Env Spikes
Membrane Env Liposomes as a Platform for Immunization with Membrane-Incorporated HIV Env Spikes
Jon Steichen,
The Scripps Research Institute, USA
Germline-Targeting for HCDR3-Dependent Broadly Neutralizing Antibodies
Germline-Targeting for HCDR3-Dependent Broadly Neutralizing Antibodies
5:00—7:00 PM
New Approaches in Vaccine Clinical Trial Design
*
Anna P. Durbin,
Johns Hopkins Bloomberg School of Public Health, USA
Thomas Evans,
TomegaVax, USA
Mathematical Modeling of Human Immune Responses to Design more Efficient Vaccine Clinical Development
Mathematical Modeling of Human Immune Responses to Design more Efficient Vaccine Clinical Development
Ashley J. Birkett,
PATH, USA
New Approaches in Vaccine Clinical Trial Design: Maximizing Malaria Vaccine Efficacy and Informing Next-Generation Efforts
New Approaches in Vaccine Clinical Trial Design: Maximizing Malaria Vaccine Efficacy and Informing Next-Generation Efforts
Chris Gast,
PATH, USA
Novel and More Efficient Vaccine Clinical Trials using Adaptive Designs
Novel and More Efficient Vaccine Clinical Trials using Adaptive Designs
Maryam Mukhamedova,
NIAID, National Institutes of Health, USA
Short Talk: RSV Antibody Repertoire Analysis from Memory B Cells from RSV DS-Cav1-Vaccinated Adult Volunteers
Short Talk: RSV Antibody Repertoire Analysis from Memory B Cells from RSV DS-Cav1-Vaccinated Adult Volunteers
5:00—7:15 PM
New Insights into HIV/SIV Env Biology and the Function of Non-Neutralizing Antibodies
Stuart J. Neil,
King's College London, UK
Resistance of Transmitted Founder HIV-1 to IFITM-Mediated Restriction
Resistance of Transmitted Founder HIV-1 to IFITM-Mediated Restriction
*
Beatrice H. Hahn,
University of Pennsylvania, USA
SIVcpz and SIVgor Env-Based Immunogens
SIVcpz and SIVgor Env-Based Immunogens
Michael Farzan,
The Scripps Research Institute, USA
eCD4-Ig Unmasks Epitopes of Non-neutralizing Antibodies in Patient Serum to Mediate Potent ADCC
eCD4-Ig Unmasks Epitopes of Non-neutralizing Antibodies in Patient Serum to Mediate Potent ADCC
Lars Hangartner,
The Scripps Research Institute, USA
Short Talk: Low-Dose PGT121 Sterilely Protects Macaques in an FcγR-independent Manner from Vaginal Challenge with SHIVSF163P3
Short Talk: Low-Dose PGT121 Sterilely Protects Macaques in an FcγR-independent Manner from Vaginal Challenge with SHIVSF163P3
Susan Zolla-Pazner,
Icahn School of Medicine at Mount Sinai, USA
Short Talk: Induction with V1V2-scaffold Protein Immunogens of Cross-Clade Reactive V2-specific Effector Antibodies with Fc-Mediated Antiviral Functions
Short Talk: Induction with V1V2-scaffold Protein Immunogens of Cross-Clade Reactive V2-specific Effector Antibodies with Fc-Mediated Antiviral Functions
7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
8:00—11:30 AM
New Tools in Vaccine Manufacturing and Product Analytics
Sangeetha L. Sagar,
Sanofi Pasteur, USA
Advances and Challenges in Vaccine Development and Manufacture
Advances and Challenges in Vaccine Development and Manufacture
*
Andrew Lees,
Fina Biosolutoins, USA
Talk Title to be Announced
Talk Title to be Announced
Coffee Break
James N. Thomas,
Just Biotherapeutics, USA
Low-Cost Manufacturing and more Stable Immunobiologics for Use in Low and Middle Income Countries
Low-Cost Manufacturing and more Stable Immunobiologics for Use in Low and Middle Income Countries
Phillip W. Berman,
University of California, Santa Cruz, USA
Breaking the Logjam in HIV Envelope Vaccine Production: Robotics and Gene Editing to Improve Upstream and Downstream Manufacturing Processes
Breaking the Logjam in HIV Envelope Vaccine Production: Robotics and Gene Editing to Improve Upstream and Downstream Manufacturing Processes
Mark S. Fife,
Pirbright Institute, UK
Short Talk: Gene Knockout Technology of Chicken Interferon Inducible Transmembrane Proteins (chIFITMs) for Increased Vaccine Production
Short Talk: Gene Knockout Technology of Chicken Interferon Inducible Transmembrane Proteins (chIFITMs) for Increased Vaccine Production
Gabriel Byrne,
University of California, Santa Cruz, USA
Short Talk: Use of Gene Editing for the Development of an Mgat1 Deficient CHO Cell Line Suitable for GMP Manufacturing of HIV Vaccines
Short Talk: Use of Gene Editing for the Development of an Mgat1 Deficient CHO Cell Line Suitable for GMP Manufacturing of HIV Vaccines
Caroline B. Kjaerulff Mathiesen,
Metropolitan University College, University of Copenhagen, Denmark
Short Talk: Genetically Engineered Cell Factories Produce Glycoengineered Vaccines that Target Antigen Presenting Cells and Alter Immunity
Short Talk: Genetically Engineered Cell Factories Produce Glycoengineered Vaccines that Target Antigen Presenting Cells and Alter Immunity
8:00—11:15 AM
Induction of Broad Neutralizing Antibodies by Vaccination
Leonidas Stamatatos,
Fred Hutchinson Cancer Research Center, USA
Targeted Expansion and Maturation of bNAb B Cell Precursors
Targeted Expansion and Maturation of bNAb B Cell Precursors
*
John R. Mascola,
NIAID, National Institutes of Health, USA
Strategies to Elicit HIV-1 Fusion Peptide Directed Neutralizing Antibodies
Strategies to Elicit HIV-1 Fusion Peptide Directed Neutralizing Antibodies
Coffee Break
William Schief,
International AIDS Vaccine Initiative and The Scripps Research Institute, USA
Toward Elicitation of Broadly Neutralizing Antibodies by Germline-Targeted Priming and Structure-Guided Boosting
Toward Elicitation of Broadly Neutralizing Antibodies by Germline-Targeted Priming and Structure-Guided Boosting
Rogier W. Sanders,
University of Amsterdam and Weill Cornell Medical College, Netherlands
Native-Like HIV-1 Envelope Trimers as a Platform to Activate Germline Precursors of Broadly Neutralizing Antibodies
Native-Like HIV-1 Envelope Trimers as a Platform to Activate Germline Precursors of Broadly Neutralizing Antibodies
Nicole A. Doria-Rose,
NIAID, National Institutes of Health, USA
Short Talk: Development of Three MPER-directed Neutralizing Antibody Lineages in an HIV Infected Individual
Short Talk: Development of Three MPER-directed Neutralizing Antibody Lineages in an HIV Infected Individual
Kevin O. Saunders,
Duke University, USA
Short Talk: Modification of HIV Env Glycosylation Augments Binding to Unmutated Common Ancestor and Intermediate Antibodies of V3-Glycan Broadly Neutralizing Antibody Lineages
Short Talk: Modification of HIV Env Glycosylation Augments Binding to Unmutated Common Ancestor and Intermediate Antibodies of V3-Glycan Broadly Neutralizing Antibody Lineages
1:00—2:30 PM
Meet the Editors Panel (Joint)
Panel for Students, Postdocs, and Young Investigators to Meet with Journal Editors
Sonja Schmid,
Nature Publishing Group, USA
Kavitha Scranton,
Immunity, USA
Andrew J. Rennekamp,
Cell Press, USA
Lindsey Pujanandez,
Science Translational Medicine, USA
2:30—4:30 PM
Workshop 3: How Best to Meet the Increasing Challenges Faced in Vaccine Development
*
Tong-Ming Fu,
Merck Research Laboratories, USA
Bruno Emanuel Correia,
École Polytechnique Fédérale de Lausanne, Switzerland
On the Development of Precision Vaccines through Epitope-Focused Immunogens: A Case Study on RSV
On the Development of Precision Vaccines through Epitope-Focused Immunogens: A Case Study on RSV
Lan Zhang,
Merck, USA
Design and Characterization of an Improved Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus
Design and Characterization of an Improved Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus
Michael J. Moser,
FluGen, Inc., USA
Single-Replication Influenza B Virus Vaccine BM2SR Provides Sterilizing Immunity and Cross-Lineage Protection by Inducing both Cellular and Cytokine Responses in Mice
Single-Replication Influenza B Virus Vaccine BM2SR Provides Sterilizing Immunity and Cross-Lineage Protection by Inducing both Cellular and Cytokine Responses in Mice
Masaru Kanekiyo,
NIAID, National Institutes of Health, USA
Targeting the Conserved Stem Supersite on Influenza Virus Hemagglutinin by Human Ighd-Encoded Innate-Like Element
Targeting the Conserved Stem Supersite on Influenza Virus Hemagglutinin by Human Ighd-Encoded Innate-Like Element
Rahul Shukla,
International Centre for Genetic Engineering and Biotechnology, India
“Four-in-One” Envelope-based mosaic VLPs Elicit Tetravalent Neutralizing Antibody Response Devoid of Enhancement Potential in Mice
“Four-in-One” Envelope-based mosaic VLPs Elicit Tetravalent Neutralizing Antibody Response Devoid of Enhancement Potential in Mice
Guangzu Zhao,
University of Queensland, Australia
Self-Adjuvanting and Self-Assembling Lipid Core Peptide Vaccines against Human Hookworm Parasite
Self-Adjuvanting and Self-Assembling Lipid Core Peptide Vaccines against Human Hookworm Parasite
Wessam Melik,
Orebro University, Sweden
Development of an Edible TBEV Vaccine
Development of an Edible TBEV Vaccine
Rocio Jimenez-Martinez,
Griffith University-QIMRB, Australia
Investigating Venom Derived Molecules that Augment Human Immune Function
Investigating Venom Derived Molecules that Augment Human Immune Function
5:00—6:45 PM
New Tools in Vaccine Formulation and Delivery
*
David C. Kaslow,
PATH, USA
Nathalie Garçon,
Bioaster, France
Adjuvants in Vaccines: From Aluminium to AS01: What Path for their Development and Licensure?
Adjuvants in Vaccines: From Aluminium to AS01: What Path for their Development and Licensure?
Rhea N. Coler,
Infectious Disease Research Institute, USA
Enhancing Immunogenicity and Protective Efficacy through Novel Adjuvants and Formulations
Enhancing Immunogenicity and Protective Efficacy through Novel Adjuvants and Formulations
Patrick M. Reeves,
Massachusetts General Hospital, USA
Accelerated Development of a T Cell-Based Vaccine for Q Fever
Accelerated Development of a T Cell-Based Vaccine for Q Fever
5:00—7:00 PM
Antibodies as Immunoprophylaxis and Treatment
Marina F. Caskey,
Rockefeller University, USA
Effects of Potent Broad Neutralizing Antibody Combinations in Humans
Effects of Potent Broad Neutralizing Antibody Combinations in Humans
Julie Ledgerwood,
NIAID, National Institutes of Health, USA
Passive Immunization of HIV-1 Neutralizing Monoclonal Antibodies in Clinical Trials
Passive Immunization of HIV-1 Neutralizing Monoclonal Antibodies in Clinical Trials
*
David D. Ho,
Aaron Diamond AIDS Research Center, USA
Engineering HIV-Neutralizing Bispecific Antibodies
Engineering HIV-Neutralizing Bispecific Antibodies
Peter D. Kwong,
NIAID, National Institutes of Health, USA
Short Talk: Recognition by Antibody of All Major Exposed Regions of the Prefusion Closed HIV-1 Env Trimer
Short Talk: Recognition by Antibody of All Major Exposed Regions of the Prefusion Closed HIV-1 Env Trimer
7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
8:00—11:00 PM
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:
|
|
|
|
We gratefully acknowledge additional support for this conference from:
|
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
